StreetInsider.com News Articles

MBX Biosciences to Participate in Upcoming November Investor Conferences

Tue, 13 Oct 2026 08:00:00 -0400

CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:

Guggenheim 3rd Annual Healthcare Innovation Conference
Date: Tuesday, November 10, 2026
Format: Fireside Chat and 1x1 meetings
Time: 11:00 – 11:25 a.m. EST
Location: Boston, MA

UBS Global Biopharma Conference
Date: Tuesday,

MBX Biosciences to Participate in Upcoming November Investor Conferences

Tue, 13 Oct 2026 08:00:00 -0400

Guggenheim 3rd Annual Healthcare Innovation Conference
Date: Tuesday, November 10, 2026
Format: Fireside Chat and 1x1 meetings
Time: 11:00 – 11:25 a.m. EST
Location: Boston, MA

UBS Global Biopharma Conference
Date: Tuesday,

MBX Biosciences Inc (MBX) PT Raised to $84 at Stifel

Mon, 12 Oct 2026 05:15:30 -0400

Stifel analyst Annabel Samimy raised the price target on MBX Biosciences Inc (NASDAQ: MBX) to $84.00 (from $70.00) while maintaining a Buy rating.

The analyst comments "We reiterate our Buy rating on MBX, raising our TP to $84. MBX is approaching its Part-C readout from the Ph.1 trial of MBX-4291 (monthly GLP-1/GIP) in obesity, following already strong indications from the Part-B portion that showed the intended characteristics of its smooth PK profile—high tolerability with a long half-life that allows for monthly dosing. Part C will be the first unblinded look following a unique, self-titrating regimen that reached -7% blinded weight loss/WL,

MBX Biosciences Inc (MBX) PT Raised to $84 at Stifel

Mon, 12 Oct 2026 05:15:30 -0400

Stifel analyst Annabel Samimy raised the price target on MBX Biosciences Inc (NASDAQ: MBX) to $84.00 (from $70.00) while maintaining a Buy rating.

Microbix Making Keynote Presentation at Masters Summit 2026

Thu, 08 Oct 2026 07:00:00 -0400

MISSISSAUGA, ON / ACCESS Newswire / October 8, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF), Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to its life sciences clients and peers at the Masters Summit 2026, organized by leading eQMS provider MasterControl, Inc. and being hosted at the Hyatt Regency in Salt Lake City, Utah on October 12-15, 2026.

Microbix's Manager of IT, Dmytro Panchenko, and QC Project Lead Semiramida (Nina) Markosyan, will present to 600+ specialist attendees at the Masters Summit 2026 about the Company's successful onboarding and

Microbix Making Keynote Presentation at Masters Summit 2026

Thu, 08 Oct 2026 07:00:00 -0400

MBX Biosciences Inc (MBX) PT Raised to $150 at Guggenheim

Fri, 02 Oct 2026 06:49:03 -0400

(Updated - October 2, 2026 6:49 AM EDT)

Guggenheim analyst Seamus Fernandez raised the price target on MBX Biosciences Inc (NASDAQ: MBX) to $150.00 (from $88.00) while maintaining a Buy rating.

The analyst commented: "We are raising our PT to $150 (from $88 prior) driven by our updated estimates for MBX 4291, potential once monthly GLP/GIP for obesity, following our proprietary obesity survey and our comps analysis ahead of 12-wk obesity data in 4Q26. Our survey of high-volume obesity-treating physicians (n=30; see HERE indicated: (1) the market will continue to expand; (2) GI tolerability is a leading cause of discontinuation and a

MBX Biosciences Inc (MBX) PT Raised to $150 at Guggenheim

Fri, 02 Oct 2026 06:49:03 -0400

(Updated - October 2, 2026 6:49 AM EDT)

Guggenheim analyst Seamus Fernandez raised the price target on MBX Biosciences Inc (NASDAQ: MBX) to $150.00 (from $88.00) while maintaining a Buy rating.

UBS Reiterates Buy Rating on MBX Biosciences Inc (MBX), Says Stock Remains Undervalued

Mon, 28 Sep 2026 09:41:47 -0400

UBS analyst Michael Yee reiterated a Buy rating and $90.00 price target on MBX Biosciences Inc (NASDAQ: MBX).

The analyst commented, "We hosted MBX’s new mgmt team on the road last week and came away more bullish on the stock. The key focus for the stock remains the 12-week obesity readout for the lead long-acting GLP1/GIPR program in Q4. We like the program and believe it could present a compelling profile with competitive weight loss (6-9% at week 12), a potentially cleaner GI tolerability profile, and oncemonthly dosing. Overall, we like the stock, with the weekly PTH program already in Phase

Microbix Presenting at Muskoka Capital Event

Wed, 23 Sep 2026 07:00:00 -0400

MISSISSAUGA, ON / ACCESS Newswire / September 23, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix^®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Muskoka Capital Event, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 25 to 27, 2025.

Microbix's CEO, Cameron Groome, and Director of Product Management, Pavel Zhelev, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of the event. The presentation slides to which they

Microbix Presenting at Muskoka Capital Event

Wed, 23 Sep 2026 07:00:00 -0400

Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers

Wed, 09 Sep 2026 07:00:00 -0400

MISSISSAUGA, ON / ACCESS Newswire / September 9, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has completed formal qualification to become a supplier for five in-vitro diagnostics (IVD) manufacturers ("Dx Test-Makers"). Each of these five Dx Test-Makers are considered to be one of the ten largest such companies by revenues, and Microbix is pleased to have successfully completed their supplier audit & quality review processes.

Clearing these detailed and multifaceted supplier qualification processes permits Microbix to supply critical products to these Dx Test-makers, across

Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers

Wed, 09 Sep 2026 07:00:00 -0400

Clearing these detailed and multifaceted supplier qualification processes permits Microbix to supply critical products to these Dx Test-makers, across

Form 8-K MBX Biosciences, Inc. For: Aug 27

Thu, 27 Aug 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260827/26985528.html

Form 8-K MBX Biosciences, Inc. For: Aug 27

Thu, 27 Aug 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260827/26985528.html

MBX Biosciences doses first patient in Phase 3 hypoparathyroidism trial